U.S. markets closed
  • S&P Futures

    4,531.25
    -5.25 (-0.12%)
     
  • Dow Futures

    35,515.00
    -42.00 (-0.12%)
     
  • Nasdaq Futures

    15,325.25
    -15.75 (-0.10%)
     
  • Russell 2000 Futures

    2,284.20
    -4.60 (-0.20%)
     
  • Crude Oil

    84.49
    +0.73 (+0.87%)
     
  • Gold

    1,795.20
    -1.10 (-0.06%)
     
  • Silver

    24.41
    -0.04 (-0.18%)
     
  • EUR/USD

    1.1648
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3771
    +0.0011 (+0.08%)
     
  • USD/JPY

    113.6150
    +0.1550 (+0.14%)
     
  • BTC-USD

    61,741.72
    +655.93 (+1.07%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,593.21
    -211.64 (-0.73%)
     

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAINESVILLE, Fla., September 08, 2021--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning on Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.cyclotherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005214/en/

Contacts

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
CYTH@jtcir.com